Benjamin Halladay - 14 Mar 2025 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
Chief Financial Officer
Signature
/s/ Sheldon L. Koenig, by power of attorney
Issuer symbol
ESPR
Transactions as of
14 Mar 2025
Net transactions value
$0
Form type
4
Filing time
17 Mar 2025, 17:16:56 UTC
Previous filing
20 Feb 2025
Next filing
19 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ESPR Common Stock Award $0 +238,000 +96% $0.000000 485,245 14 Mar 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ESPR Stock Option (right to buy) Award $0 +213,000 $0.000000 213,000 14 Mar 2025 Common Stock 213,000 $1.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be in June 15, 2025.
F2 Includes 6,574 shares recently acquired in Esperion's Employee Stock Purchase Plan.